79 related articles for article (PubMed ID: 18590277)
1. Artificial ion channel biosensor in human immunodeficiency virus gp41 drug sensing.
Hou Y; Gochin M
Anal Chem; 2008 Aug; 80(15):5924-9. PubMed ID: 18590277
[TBL] [Abstract][Full Text] [Related]
2. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
[TBL] [Abstract][Full Text] [Related]
3. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.
Mo H; Konstantinidis AK; Stewart KD; Dekhtyar T; Ng T; Swift K; Matayoshi ED; Kati W; Kohlbrenner W; Molla A
Virology; 2004 Nov; 329(2):319-27. PubMed ID: 15518811
[TBL] [Abstract][Full Text] [Related]
4. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
[TBL] [Abstract][Full Text] [Related]
5. An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor.
Mische CC; Yuan W; Strack B; Craig S; Farzan M; Sodroski J
Virology; 2005 Jul; 338(1):133-43. PubMed ID: 15950253
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.
Desmezieres E; Gupta N; Vassell R; He Y; Peden K; Sirota L; Yang Z; Wingfield P; Weiss CD
J Virol; 2005 Apr; 79(8):4774-81. PubMed ID: 15795263
[TBL] [Abstract][Full Text] [Related]
7. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
8. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
9. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Liu S; Boyer-Chatenet L; Lu H; Jiang S
J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the interaction of two peptides from the N terminus of the NHR domain of HIV-1 gp41 with phospholipid membranes.
Moreno MR; Guillén J; Pérez-Berna AJ; Amorós D; Gómez AI; Bernabeu A; Villalaín J
Biochemistry; 2007 Sep; 46(37):10572-84. PubMed ID: 17711304
[TBL] [Abstract][Full Text] [Related]
11. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
12. Development of a FRET assay for monitoring of HIV gp41 core disruption.
Xu Y; Hixon MS; Dawson PE; Janda KD
J Org Chem; 2007 Aug; 72(18):6700-7. PubMed ID: 17685571
[TBL] [Abstract][Full Text] [Related]
13. A homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion.
Smeulders L; Bunkens L; Vereycken I; Van Acker K; Holemans P; Gustin E; Van Loock M; Dams G
Methods Mol Biol; 2013; 1030():11-7. PubMed ID: 23821256
[TBL] [Abstract][Full Text] [Related]
14. Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: implication for mode of action.
Lev N; Fridmann-Sirkis Y; Blank L; Bitler A; Epand RF; Epand RM; Shai Y
Biochemistry; 2009 Apr; 48(14):3166-75. PubMed ID: 19206186
[TBL] [Abstract][Full Text] [Related]
15. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
Korazim O; Sackett K; Shai Y
J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
[TBL] [Abstract][Full Text] [Related]
16. Fatty acids can substitute the HIV fusion peptide in lipid merging and fusion: an analogy between viral and palmitoylated eukaryotic fusion proteins.
Lev N; Shai Y
J Mol Biol; 2007 Nov; 374(1):220-30. PubMed ID: 17919659
[TBL] [Abstract][Full Text] [Related]
17. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.
Yu H; Tudor D; Alfsen A; Labrosse B; Clavel F; Bomsel M
Retrovirology; 2008 Oct; 5():93. PubMed ID: 18925934
[TBL] [Abstract][Full Text] [Related]
18. Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.
Cai L; Balogh E; Gochin M
Antimicrob Agents Chemother; 2009 Jun; 53(6):2444-9. PubMed ID: 19364877
[TBL] [Abstract][Full Text] [Related]
19. [1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane].
Sun W; Wang HT; Xia CL; Wu SG; Jiang SB; Jiang ZH; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1127-31. PubMed ID: 18676243
[TBL] [Abstract][Full Text] [Related]
20. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution.
Watabe T; Terakawa Y; Watanabe K; Ohno H; Nakano H; Nakatsu T; Kato H; Izumi K; Kodama E; Matsuoka M; Kitaura K; Oishi S; Fujii N
J Mol Biol; 2009 Sep; 392(3):657-65. PubMed ID: 19616557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]